# Sonormed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sonormed

- Industry: Software
- Headquarters: Hamburg, Germany
- Website: www.tinnitracks.com
- Latest round: Series A (Apr 1, 2015)
- Investors on record: 2

## About

Sonormed develops innovative tinnitus therapies through a personalized web application that utilizes music to address tinnitus symptoms based on individual frequencies, enhancing auditory health and patient quality of life.Founded in 2012, Sonormed operates from Hamburg, Germany, focusing on tinnitus treatment through advanced digital solutions. The company was established independently and has undergone no notable pivots. Currently, there are no known subsidiaries or parent companies. The company has completed two funding rounds, with the most recent deal occurring on January 23, 2025.Sonormed specializes in tinnitus therapy via its web application, Tinnitracks, which allows users to personalize and filter music to target their unique tinnitus frequencies ranging from 200 Hz to 20 kHz. This service is intended for individuals with subjective chronic tinnitus and less than 60 dB HL hearing loss, complementing care from ENT professionals. By soothing hyperactive nerve cells in the auditory brain, Tinnitracks aims to provide long-term relief, catering to clients mainly in Europe, North America, and parts of Asia, including both consumers and healthcare providers.Sonormed's revenue model is subscription-based, allowing users to access Tinnitracks for personalized tinnitus therapy. Users must engage with the platform by listening to tailored music tracks for a minimum of 90 minutes daily over a 12-month period. While specific pricing details are not disclosed, the model relies on recurring subscription fees and potential partnerships with healthcare entities recommending Tinnitracks. The flagship product, Tinnitracks Neuro-Therapie, is protected under patent No. US 9,549,269 B2.In January 2025, Sonormed was acquired by InfectoPharm Arzneimittel und Consilium GmbH for an undisclosed amount. This acquisition is expected to enhance InfectoPharm's portfolio in ENT medicine and foster the development of innovative digital health solutions for tinnitus patients. The company plans to leverage this transition to expand its offerings, although specific new products and market expansion details have not been publicly disclosed.

## Funding rounds

- Series A, Apr 1, 2015 — High-Tech Gruenderfonds, Innovationsstarter Fonds Hamburg

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Series A
- Innovationsstarter Fonds Hamburg (https://capitalatlas.ai/funds/innovationsstarter-fonds-hamburg) — Series A